Menu
VJHemOnc Podcast
Podcast image
iwAL 2022 Session II: novel treatment strategies in ALL
19 mins; November 04, 2022
iwAL 2022 Session II: Novel treatment strategies in ALL
19 mins; November 04, 2022
The role of the innate immune system in MDS
15 mins; November 02, 2022
The role of the innate immune system in MDS
15 mins; November 02, 2022
iwAL 2022 Session I: the standard of care in AML in 2022
17 mins; October 28, 2022
iwAL 2022 Session I: The standard of care in AML in 2022
17 mins; October 28, 2022
iwNHL 2022 Session I: advances in the treatment of T-cell lymphoma
17 mins; October 26, 2022
iwNHL 2022 Session I: Advances in the treatment of T-cell lymphoma
17 mins; October 26, 2022
ISA 2022: meeting highlights and recent updates in amyloidosis
12 mins; October 21, 2022
ISA 2022: meeting highlights and recent updates in amyloidosis
12 mins; October 21, 2022
Highlights from IMS 2022: managing high-risk & frail patients with myeloma and the prognostic value of MRD
16 mins; October 13, 2022
Highlights from IMS 2022: managing high-risk & frail patients with myeloma and the prognostic value of MRD
16 mins; October 13, 2022
Highlights from the 2022 Texas MPN Workshop: early intervention, disease progression & future targets
7 mins; October 07, 2022
Highlights from the 2022 Texas MPN Workshop: early intervention, disease progression & future targets
7 mins; October 07, 2022
iwMDS 2022: Key highlights
15 mins; September 29, 2022
iwMDS 2022: Key highlights
15 mins; September 29, 2022
Identifying high-risk myeloma and improving treatment strategies in these patients
17 mins; September 22, 2022
Identifying high-risk myeloma and improving treatment strategies in these patients
17 mins; September 22, 2022
Improving the efficiency of drug approvals in MDS
16 mins; September 14, 2022
Improving the efficiency of drug approvals in MDS
16 mins; September 14, 2022
Highlights from the 2022 Texas MPN Workshop: advances in MPN treatment
12 mins; September 09, 2022
Highlights from the 2022 Texas MPN Workshop: advances in MPN treatment
12 mins; September 09, 2022
The need for more effective first-line therapies in MDS
9 mins; September 07, 2022
The need for more effective first-line therapies in MDS
9 mins; September 07, 2022
Myeloma 2022: day two highlights
11 mins; September 02, 2022
Myeloma 2022: day two highlights
11 mins; September 02, 2022
The promise of CAR-T therapy in CLL and challenges in the field
16 mins; August 31, 2022
The promise of CAR-T therapy in CLL and challenges in the field
16 mins; August 31, 2022
Clonal hematopoiesis and pre-MDS states
8 mins; August 24, 2022
Clonal hematopoiesis and pre-MDS states
8 mins; August 24, 2022
T-cell engagers in multiple myeloma: current challenges and future outlooks
20 mins; August 24, 2022
T-cell engagers in multiple myeloma: current challenges and future outlooks
20 mins; August 24, 2022
High-risk MDS: unmet needs and future treatment approaches
7 mins; August 19, 2022
High-risk MDS: unmet needs and future treatment approaches
7 mins; August 19, 2022
The importance of patient-reported outcomes in CAR-T recipients
5 mins; August 17, 2022
The importance of patient-reported outcomes in CAR-T recipients
5 mins; August 17, 2022
CAR-T therapy in myeloma and lymphoma
16 mins; August 12, 2022
CAR-T therapy in myeloma and lymphoma
16 mins; August 12, 2022
CAR-T therapy in AML: challenges and future outlooks
25 mins; August 10, 2022
CAR-T therapy in AML: challenges and future outlooks
25 mins; August 10, 2022
The current state of CAR-T therapy in lymphoma
11 mins; August 05, 2022
The current state of CAR-T therapy in lymphoma
11 mins; August 05, 2022
Myeloma treatment updates from EHA 2022
13 mins; August 03, 2022
Myeloma treatment updates from EHA 2022
13 mins; August 03, 2022
Updates in classification and risk stratification in MDS
12 mins; July 27, 2022
Updates in classification and risk stratification in MDS
12 mins; July 27, 2022
Myeloma 2022: day one highlights
11 mins; July 27, 2022
Myeloma 2022: day one highlights
11 mins; July 27, 2022
Immune dysregulation and targeting in MDS
12 mins; July 22, 2022
Immune dysregulation and targeting in MDS
12 mins; July 22, 2022
The future of CAR-T therapy in ALL
12 mins; July 20, 2022
The future of CAR-T therapy in ALL
12 mins; July 20, 2022
An insight into novel targets in myeloma and mechanisms of resistance to PIs and IMiDs
16 mins; July 15, 2022
An insight into novel targets in myeloma and mechanisms of resistance to PIs and IMiDs
16 mins; July 15, 2022
Key updates in the treatment and management of MPNs
13 mins; July 08, 2022
Key updates in the treatment and management of MPNs
13 mins; July 08, 2022
Addressing unmet needs and future treatment approaches in AL amyloidosis
10 mins; July 01, 2022
Addressing unmet needs and future treatment approaches in AL amyloidosis
10 mins; July 01, 2022
Myeloma treatment in the UK: updates from Muk Nine b: OPTIMUM & the importance of genomics
11 mins; June 24, 2022
Myeloma treatment in the UK: updates from Muk Nine b: OPTIMUM & the importance of genomics
11 mins; June 24, 2022
Updates in lymphoma and CLL treatment in the UK
8 mins; June 17, 2022
Updates in lymphoma and CLL treatment in the UK
8 mins; June 17, 2022
The importance of early interception and intervention in myeloma
6 mins; June 07, 2022
The importance of early intervention and interception in myeloma
6 mins; June 07, 2022
Impact of the COVID-19 pandemic on the EBMT & projects in the pipeline
36 mins; June 03, 2022
Impact of the COVID-19 pandemic on the EBMT & projects in the pipeline
36 mins; June 03, 2022
CAR-T and lymphoma treatment in the UK
18 mins; May 27, 2022
CAR-T and lymphoma treatment in the UK
18 mins; May 27, 2022
Harnessing the power of immunotherapy in myeloma and amyloidosis
10 mins; May 20, 2022
Harnessing the power of immunotherapy in myeloma and amyloidosis
10 mins; May 20, 2022
The impact of AI and machine learning algorithms in MDS
45 mins; May 13, 2022
The impact of AI and machine learning algorithms in MDS
45 mins; May 13, 2022
MMRF-CoMMpass: the genomic basis of myeloma subtypes
3 mins; May 06, 2022
MMRF-CoMMpass: the genomic basis of myeloma subtypes
3 mins; May 06, 2022
Click here to see more
Useful pages

Apply to teach

Reviews

Help & FAQs

Blog

Spanish Podcast

French Podcast

Italian Podcast

About Us

Contact Us

Terms & Privacy

Find a tutor

Arabic tutors

Chinese tutors

Dutch tutors

English tutors

French tutors

German tutors

Greek tutors

Italian tutors

Japanese tutors

Korean tutors

Portuguese tutors

Romanian tutors

Russian tutors

Spanish tutors

Swedish tutors

Thai tutors

More languages soon!

Languages

Learn Arabic

Learn Chinese

Learn Dutch

Learn English

Learn French

Learn German

Learn Greek

Learn Italian

Learn Japanese

Learn Korean

Learn Portuguese

Learn Romanian

Learn Russian

Learn Spanish

Learn Swedish

Learn Thai

© 2026 LanguaTalk, All Rights Reserved